Why the study?
Do selective serotonin reuptake inhibitors (SSRIs) increase the risk of gastrointestinal bleeding?
Do selective serotonin reuptake inhibitors (SSRIs) increase the risk of gastrointestinal bleeding?
This review examines the theoretical and clinical evidence regarding the risk of gastrointestinal bleeding associated with SSRI use due to platelet serotonin depletion.
Potential SSRI-GI bleed risk via platelet effects merits awareness; leaves open need for RCTs before changing practice.
Gastroprotection may be justified in some patients T here are theoretical reasons for believing that selective serotonin reuptake inhibitors (SSRIs), widely used to treat depression, might increase the risk of gastrointestinal bleeding. Gastroprotective drugs are advocated for high risk patients taking non-steroidal anti-inflammatory drugs, another class of drug that causes gastrointestinal bleeding. What is the evidence that this advice should be extended to patients receiving SSRIs? Serotonin is released from platelets in response to vascular injury and promotes vasoconstriction and a change in the shape of the platelets that leads to aggregation.1 Platelets cannot themselves synthesise serotonin. SSRIs inhibit the serotonin transporter, which is responsible for the uptake of serotonin into platelets. It could thus be predicted that SSRIs would deplete platelet serotonin, leading to a reduced ability to form clots and a subsequent increase in the risk of bleeding. We have reviewed the published database studies on the relation between SSRI use and gastrointestinal bleeding. Four of these studies compared the risk of an upper gastrointestinal bleed in those …
No takes yet. Share an insight, caveat, or question.
Paton et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: